Eric Lefkofsky, Tempus and a New Stage for Cancer Medicine

In the United States of America, almost 40 percent of adults are probably going to face a diagnosis of cancer at some point in their lives. The National Cancer Institute issued that nearly 14.5 million of the U. S. citizens had cancer in 2014. The most alarming thing is that by 2024, that figure is expected to skyrocket to over 19 million people.

Statistics and prognosis such as these create a sense of urgency to fight against the unwanted yet very possible future. Scientists such as Mr. Eric Lefkofsky have created businesses such a Tempus in order to join the fight against cancer. Medicine has entered an era of data-driven conclusions and Tempu it somewhat of a leader in data analysis in medicine that more data-enabled and precise.

Even though EHRs or electronic health records has become popular as a concept, it is not widely used in medicine Tempus aims to change that and achieve the lofty goal in transforming the way patients receive cancer care. The system at Tempus is able to analyze the clinical data of the patients as well as their molecular data. While the corporation was able to develop such a software, clinical and medical data was not as accessible or affrdable, adding to the issues that Tempus has had to overcome.

The molecular data that the Tempus system is able o analyze f predominantly genomic information whc=ich is collected through human genome sequencing. Such procedures used to be exorbitantly expensive and when it was first mapped out, it cost more than 100 million dollars. Nowadays, however, the process has dropped in price considerably allowing more institutions to take advantage of. Although it is still pricey with its coast of 5 000 dollars, it is nowhere near what it used to cost. Tempus is trying to bring down the price further to make more accessible.

Using this procedure, Tempus can provide a treatment plan for each individual patient. Tempus combines the clinical information of a patient with their molecular data, collected through genome sequencing. This can bring a new era in cancer treatment the therapies being personalized to patients more than ever before.

Leave a Reply

Your email address will not be published. Required fields are marked *